Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 928 of 6351
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control CompletedThe purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma. The researchers will also look at the safety of the drug combination …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo aims to extend life in tough lung cancer
Disease control Recruiting nowThis phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, wor…
Phase 2 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immunotherapy drug shows promise before colon cancer surgery
Disease control CompletedThe main purpose of this study was to help meet the medical needs of people in China with certain types of solid tumors that have specific genetic changes called microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). The study looked at how well the drug tis…
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo therapy aims to wipe out esophageal cancer before surgery
Disease control OngoingThis phase II trial studies the effect of chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery in treating patients with esophageal or esophageal/gastroesophageal junction cancer that has not spread to other places in the body (non-metastatic).…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can a monthly injection stop MS in its tracks? new study aims to find out
Disease control CompletedThis study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study also assesses changes in disease using monitoring…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New immune drug STK-012 takes on tough lung cancers
Disease control Recruiting nowThis is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combinati…
Phase 1/2 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer
Disease control CompletedThe purpose of this study is to assess the efficacy, tolerability, safety, pharmacokinetic (PK) and dosimetry of 177Lu-PSMA-617, in participants with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in Japan. F…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immunotherapy duo shows promise against rare lung cancer in chinese trial
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on childhood cancers that Won't quit
Disease control PausedThis phase I trial investigates the side effects and determines the best dose of an immune cell therapy called GD2CART, as well as how well it works in treating patients with osteosarcoma or neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory)…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can shedding pounds reboot the Heart's exercise engine?
Knowledge-focused CompletedThe goal of this study is to define how treatment of obesity impacts cardiometabolic performance during exercise in patients with established HFpEF or at risk for HFpEF. Multi-dimensional physical activity, including 6 minute walk distance, resting metabolic rate, the metabolic c…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New Two-Punch strategy aims to control aggressive prostate cancer
Disease control OngoingThe goal of this clinical research is to find if sequential therapy with combined androgen deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a new hormonal agent (abiraterone, enzalutamide, or apalutamide) followed by chemohormonal therap…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Blood test may predict when lung cancer returns after immunotherapy
Diagnosis OngoingThis study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)
Sponsor: Fang Wu • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Proton beam offers new hope for recurrent tumors
Disease control Recruiting nowThe goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated w…
Sponsor: The New York Proton Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can a tiny valve replace Open-Heart surgery for the long haul?
Disease control OngoingThe objective of this study is to evaluate the long term safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve system in real world setting.
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedPhase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117(Anti-CD47 Antibody)with or without chemotherapy in advanced malignant tumors
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
App aims to slash HIV rates in young transgender women
Prevention OngoingThe LifeSkills Mobile app will be evaluated in a randomized controlled trial (RCT) among 5,000 young transgender women (YTW), ages 16-29 in the United States (U.S.). Study findings will demonstrate if the intervention will reduce HIV incidence.
Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
New granule drug could ease tumors in toddlers with NF1
Disease control OngoingThis study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulati…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a single antiplatelet drug beat aspirin after heart valve replacement?
Disease control Recruiting nowThe optimal pharmacological therapy after transcatheter aortic valve implantation (TAVI) to prevent valve thrombosis and reduce thromboembolic complications without significantly increasing the risk of bleeding is not yet fully defined and constitutes an important unmet clinical …
Phase 4 • Sponsor: Fundacin Biomedica Galicia Sur • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New study tests which treatment is best for pelvic bone cancers
Disease control Recruiting nowThis study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alo…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for brain metastases? drug combo trial opens
Disease control Recruiting nowThis is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC